Taken together, these studies highlight the mechanistic connection between GBA deficiency and α-Synuclein properties, providing unique therapeutic opportunities for reducing neurotoxicity of α-Synuclein for treatment of PD. The gene discussed is SNCA; the disease is Parkinson disease.